Margaret E Gatti-Mays, MD, MPH
Academic Title: Associate Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am section chief of Breast Medical Oncology and an associate professor in the Division of Medical Oncology at the OSUCCC – James, where I specialize in breast cancer, immunotherapy, side effects from immunotherapy and rare subtypes of breast cancer like small-cell breast cancer. My approach to cancer care is based on the latest clinical recommendations as well as evidence-based medicine. Given the complexity of breast cancer treatment, the involvement of a multidisciplinary team is vital for superior patient care. I find the study of breast cancer to be intellectually stimulating, as no two breast cancer patients are the same. Tumors may be similar in pathology, but immune responses to the tumors differ among patients and sometimes even differ in the same patient over time. Additionally, patients have different values and goals that need to be considered when creating a treatment plan. As a member of the Translational Therapeutics Program at the OSUCCC – James, my clinical research is focused on finding ways to use immunotherapy in breast cancer through evaluating novel immunotherapy agents and designing innovative clinical trials. I am passionate about finding new ways to expand the use of immunotherapy in breast cancer patients. I am also interested in studying immune-related adverse events (irAEs) in patients who have received treatment with immunotherapy. This includes learning more about who develops irAEs, which irAEs allow for continued treatment and how irAEs impact the quality of life of patients who have good responses to treatment. As an investigator on multiple early phase clinical trials, I greatly appreciate patients who choose to participate in research. Clinical trials help to advance breast cancer care, not only for the individual but the field as a whole. Participation in a clinical trial is a truly selfless act, and one that drives us toward our goal of a cancer-free world. As the old saying goes, “Yesterday’s clinical trials are tomorrow’s treatments.” In addition to my clinical and research work, I am a Fellow of the American College of Physicians and a member of Alpha Omega Alpha Honor Medical Society. I’m also active in professional societies like the Society for Immunotherapy of Cancer (SITC) and the American Society of Clinical Oncology. Within SITC, I hold several leadership positions including vice chair for the Committee for Cancer Immunotherapy Guidelines and the co-chair for the Breast Cancer Expert Panel for Cancer Immunotherapy Guidelines.
Clinical Expertise
More info for- Medical Oncology
- Immunotherapy
- Breast Cancer
Research Interests
More info for- Immunotherapy
- Breast Neoplasms
Where I See Patients
More info forStefanie Spielman Comprehensive Breast Center
1145 Olentangy River Road Columbus, Ohio 43212 800-293-5066 Location InformationEducation & Training
More info forGraduate - Epidemiology
- Emory University
100 Boisfeuillet Jones Center, Atlanta, GA
Medical School
- Georgetown University School of Medicine
3900 Nw Reservoir Rd, Washington, DC
Residency - Internal Medicine
- MedStar Georgetown University Hospital
3800 Reservoir Rd NW, Washington, DC
Fellowship - Medical Oncology
- National Cancer Institute/National Institute of Health
9609 Medical Center Dr, Bethesda, MD
- Emory University
Academic Office & Contact Information
More info forAcademic Office:
Lincoln Tower 1335
1800 Cannon Dr
Columbus, Ohio 43210Phone:
614-366-2698Email:
gatti-mays.1@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forSeptember 20, 2024Genomic and transcriptomic landscape of HER2-low breast cancer.
Bansal R, Adeyelu T, Elliott A, Walker P, Bustos MA, Rodriguez E, Accordino MK, Meisel J, Gatti-Mays ME, Hsu E, Lathrop K, Kaklamani V, Oberley M, Sledge G, Sammons SL, Graff SL
Breast Cancer Res Treat
June 19, 2024The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer.
Johnson KCC, Ni A, Quiroga D, Pariser AC, Sudheendra PK, Williams NO, Sardesai SD, Cherian M, Stover DG, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R
NPJ Breast Cancer
June 1, 2024Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.
Sukumar JS, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover DG, Gatti-Mays M, Pariser A, Sudheendra P, George MA, Lustberg M
Cancer Med
May 30, 2024Chemotherapy-induced gut microbiome disruption, inflammation, and cognitive decline in female patients with breast cancer.
Otto-Dobos LD, Grant CV, Lahoud AA, Wilcox OR, Strehle LD, Loman BR, Adarkwah Yiadom S, Seng MM, Halloy N, Russart KLG, Carpenter KM, Dawson E, Sardesai SD, Williams NO, Gatti-Mays ME, Stover DG, Sudheendra PK, Wesolowski R, Kiecolt-Glaser JK, Bailey MT, Andridge RR, Pyter LM
Brain Behav Immun
May 10, 2024Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C
Nat Commun
March 27, 2024Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C
Nat Commun
January 8, 2024Comparing the rate of immunotherapy treatment change due to toxicity by sex.
Chua KJ, Kronstedt S, Kaldany A, Srivastava A, Doppalapudi SK, Liu H, Tarhini AA, Gatti-Mays M, Gaughan E, Hu-Lieskovan S, Aljumaily R, Nepple K, Schneider B, Sterling J, Singer EA
Cancer Rep (Hoboken)
December 14, 2023Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer-Still Haven't Found What We're Looking For.
Quiroga D, Gatti-Mays ME
JAMA Oncol
November 22, 2023Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients.
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi CL, Ruddy KJ, Cathcart-Rake E, Trovato S, Dulmage B
Support Care Cancer
October 14, 2023Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls.
Johnson KC, Grimm M, Sukumar J, Schnell PM, Park KU, Stover DG, Jhawar SR, Gatti-Mays M, Wesolowski R, Williams N, Sardesai S, Pariser A, Sudheendra P, Tozbikian G, Ramaswamy B, Doto D, Cherian MA
Breast
August 16, 2023Perspectives of patients undergoing neoadjuvant chemotherapy for breast cancer during the COVID-19 pandemic.
Gaughan AA, MacEwan SR, Rush LJ, Gatti-Mays ME, Pariser AC, McAlearney AS
Cancer Rep (Hoboken)
August 14, 2023Awareness of alcohol as a breast cancer risk factor and intentions to reduce alcohol consumption among U.S. young adult women.
Alalwan MA, Long L, Hirko KA, LoConte NK, Scherr CL, Keller-Hamilton B, Atkinson L, Suraapaneni S, Gatti-Mays ME, Manne S, Mays D
Transl Behav Med
June 24, 2023The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.
Johnson KCC, Goldstein D, Tharakan J, Quiroga D, Kassem M, Grimm M, Miah A, Vargo C, Berger M, Sudheendra P, Pariser A, Gatti-Mays ME, Williams N, Stover D, Sardesai S, Wesolowski R, Ramaswamy B, Tozbikian G, Schnell PM, Cherian MA
Oncol Ther
March 1, 2023Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12.
Toney NJ, Gatti-Mays ME, Tschernia NP, Strauss J, Gulley JL, Schlom J, Donahue RN
Int Immunopharmacol
January 14, 2023A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors.
Gatti-Mays ME, Tschernia NP, Strauss J, Madan RA, Karzai FH, Bilusic M, Redman J, Sater HA, Floudas CS, Toney NJ, Donahue RN, Jochems C, Marté JL, Francis D, McMahon S, Lamping E, Cordes L, Schlom J, Gulley JL
Oncologist
November 14, 2022Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses' health study.
Asad S, Damicis A, Heng YJ, Kananen K, Collier KA, Adams EJ, Kensler KH, Baker GM, Wesolowski R, Sardesai S, Gatti-Mays M, Ramaswamy B, Eliassen AH, Hankinson SE, Tabung FK, Tamimi RM, Stover DG
Breast Cancer Res
November 3, 2022Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, Wise-Draper TM, COVID-19 and Cancer Consortium
JAMA Oncol
September 1, 2022Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity.
Li A, Chang Y, Song NJ, Wu X, Chung D, Riesenberg BP, Velegraki M, Giuliani GD, Das K, Okimoto T, Kwon H, Chakravarthy KB, Bolyard C, Wang Y, He K, Gatti-Mays M, Das J, Yang Y, Gewirth DT, Ma Q, Carbone D, Li Z
J Immunother Cancer
July 10, 2022Living with Advanced Breast Cancer: A Descriptive Analysis of Survivorship Strategies.
Grimm M, Radcliff L, Giles M, Nash R, Holley E, Panda S, Brophy L, Williams N, Cherian M, Stover D, Gatti-Mays ME, Wesolowski R, Sardesai S, Sudheendra P, Reinbolt R, Ramaswamy B, Pariser A
J Clin Med
July 1, 2022Natural Killer Cell Recognition and Control of Epithelial Cancers.
de Souza Fernandez Pereira M, Carr DR, Gatti-Mays ME, Olsen MR, Setty BA, Shahwan KT, Lee DA
Cancer J
May 22, 2022Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases.
Schlam I, Gatti-Mays ME
Oncologist
March 11, 2022A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer.
Redman JM, Tsai YT, Weinberg BA, Donahue RN, Gandhy S, Gatti-Mays ME, Abdul Sater H, Bilusic M, Cordes LM, Steinberg SM, Marte JL, Jochems C, Kim SS, Marshall JL, McMahon S, Redmond E, Schlom J, Gulley JL, Strauss J
Oncologist
January 4, 2022Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.
Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilen MA, Caimi PF, Choueiri TK, Dawsey SJ, Fecher LA, Flora DB, Friese CR, Glover MJ, Gonzalez CJ, Goyal S, Halfdanarson TR, Hershman DL, Khan H, Labaki C, Lewis MA, McKay RR, Messing I, Pennell NA, Puc M, Ravindranathan D, Rhodes TD, Rivera AV, Roller J, Schwartz GK, Shah SA, Shaya JA, Streckfuss M, Thompson MA, Wulff-Burchfield EM, Xie Z, Yu PP, Warner JL, Shah DP, French B, Hwang C, COVID-19 and Cancer Consortium (CCC19)
JAMA Netw Open
January 1, 2022Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity.
Sieber B, Strauss J, Li Z, Gatti-Mays ME
Front Oncol
September 8, 2021Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer.
Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S
Breast Cancer Res Treat
August 12, 2021Hormone receptor-positive breast cancer and black race: does sex matter?
Eskander MF, Li Y, Bhattacharyya O, Tsung A, Oppong BA, Hamad A, Gatti-Mays M, Obeng-Gyasi S
Breast Cancer Res Treat
August 1, 2021Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK
J Immunother Cancer
June 17, 2021Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.
Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL, COVID-19 and Cancer Consortium
JAMA Oncol
March 23, 2021Improving Breast Cancer Responses to Immunotherapy-a Search for the Achilles Heel of the Tumor Microenvironment.
Jenkins S, Wesolowski R, Gatti-Mays ME
Curr Oncol Rep
February 1, 2021Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis.
Gatti-Mays M, Gulley JL
J Immunother Cancer
December 14, 2020A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.
COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org , COVID-19 and Cancer Consortium
Cancer Cell
December 1, 2020Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
Strauss J, Gatti-Mays ME, Cho BC, Hill A, Salas S, McClay E, Redman JM, Sater HA, Donahue RN, Jochems C, Lamping E, Burmeister A, Marté JL, Cordes LM, Bilusic M, Karzai F, Ojalvo LS, Jehl G, Rolfe PA, Hinrichs CS, Madan RA, Schlom J, Gulley JL
J Immunother Cancer
December 1, 2020A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.
Gatti-Mays ME, Karzai FH, Soltani SN, Zimmer A, Green JE, Lee MJ, Trepel JB, Yuno A, Lipkowitz S, Nair J, McCoy A, Lee JM
Oncologist
July 1, 2020Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.
Collins JM, Donahue RN, Tsai YT, Manu M, Palena C, Gatti-Mays ME, Marté JL, Madan RA, Karzai F, Heery CR, Strauss J, Abdul-Sater H, Cordes L, Schlom J, Gulley JL, Bilusic M
Oncologist
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Gatti-Mays has reported no relationships with companies or entities.
Patient Comments
Dr. Gatti-Mays was extremely kind, compassionate, and professional with my care. She listened to my concerns, provided me with further education, and included me in the decision making process for follow-up care. I left my appointment feeling completely heard and with total confidence in her care, which put me at ease.
I know wait time is long but I also understand that when you have cancer patients you have to take the time that each patient needs.
I can say in a few words that Dr. Margaret Gatti-Mays exceeds my expectations , I feel very safe being under her care. She is very professional, knows what she is doing and is a very kind person.
Excellent! I felt cared for and very much like this was a personalized visit.
While it takes time for the doctor to get in the room, I never feel rushed and know that she is taking the time with me like she does others.
Dr. Gati-Mays is wonderful
Dr. Gatti-Mays is wonderful in every way. Such a kind and caring doctor, and I am blessed to have her helping me on my journey.
Everyone I came in contact with was top notch.
My experience with my provider is always good. I never feel disappointed with the level of care she provides.
Dr.Gatti-Mays listened to my concerns
We have just started our journey. Staff in facilities have been absolutely excellent. As of right now we feel blessed to have found the James.
This was a first time visit having just moved to Ohio from NJ. Dr. Very thorough with explanations and exam
Always a pleasure to see Dr. Gatti-Mays! She's excellent! Her staff is, as well.
Very straight forward and matter of fact, I love this approach. Heard some things about my opportunities I had not heard before during this most recent event.
My treatment and follow-up visits were/ are well and in good results........ I feel as though Dr Gotti Mays is as happy for me as I am about my care and well-being
I love Dr Gatti-Mays
Dr Gatti- Mays is an exceptional listener and a clear communicator of treatment plan. I completely trust her expertise and appreciate her compassion and encouragement. Feel grateful to be under her care. She always takes time to be sure I feel comfortable with all matters discussed.
I am very appreciative of all the knowledge and experience the doctors have and their patience to walk through at a level that is understandable to understand. Many opportunities to ask questions. Did not feel rushed at all.
Every person I have come in contact with from the very first time through to my appointment last week have been very professional and friendly, helpful, and courteous. I can't say enough about them!
I had been freaking out about some rib pain I was having, but I was reassured, and felt so much better after the appointment.
Dr. Gatti is off the charts dedicated and is extremely knowledgeable. Very thankful for her care!
Very good
Excellent Doctor
Really pleased with personnel, doctor, & nurses.
Good.. A lot of info
Dr Gatti-Mays was so kind spent a lot of time with me and explained everything. I so appreciated her!1